Avenue Therapeutics, Inc.

ATXI Healthcare Biotechnology

Avenue Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million. In the quarter to June 2026, EPS fell 290.9% and free cash flow fell 169.9%, each against the same quarter a year earlier.

0.43 0.00 0.00%
Market cap
$680.0K
P/E
0.0×
Fwd P/E
−0.4×
Dividend yield
—
F-score
n/a
Altman Z
−51.47
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

37.93% (157.75%) (99.26%) (163.30%)
ROA
23.62% (103.84%) (57.80%) (90.50%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
32.57% (158.79%) (146.24%) (488.05%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(0.55) (0.59) (0.33) (0.42)
Free Cash Flow
(1.74) (1.83) (1.08) (1.38)
Other line items

Show all line items

Columns are period end dates